Aster DM Healthcare Reports Impressive 18% YoY Revenue Growth in Q4, Reaching ₹1,182 Crore.
Aster DM Healthcare has reported a robust financial performance for Q4, showcasing double-digit growth in both revenue and profitability as it progresses towards the completion of its merger with Quality Care India Ltd (QCIL). The company achieved an 18% year-on-year increase in revenue, reaching Rs 1,182 crore, while operational EBITDA (excluding the Kasaragod facility) surged by 31% to Rs 253 crore. Margins improved significantly from 19.3% to 21.7%, reflecting effective cost management and operational leverage. Notably, the normalized profit after tax experienced a remarkable 45% growth, totaling Rs 153 crore, underscoring the company’s robust financial health.
On a proforma basis, incorporating QCIL’s figures, the combined entity reported a revenue of Rs 2,361 crore for the quarter, maintaining an 18% year-on-year increase. The operational EBITDA showed impressive growth of 25%, amounting to Rs 517 crore, with margins slightly improved at 21.9%. Chairman Azad Moopen expressed confidence in the merger, which has garnered overwhelming shareholder support, with 96.68% voting in favor. This strong backing signals considerable trust in the company’s vision of establishing a comprehensive healthcare platform, expected to generate synergies through continued efficiencies and growth.
From an operational perspective, the growth was driven by increasing patient volumes and improved revenue realization, as evidenced by a 9% rise in average revenue per inpatient to Rs 1.25 lakh, alongside a 15% increase in overall patient volumes. The regional performance highlighted significant contributions from the Kerala and Andhra Pradesh-Telangana clusters. As the merger awaits final regulatory approvals and is anticipated to close in Q1 FY27, the company is poised to enhance its scale and operational capabilities, positioning itself among the top three healthcare providers in India with a combined total of over 10,600 beds across 28 cities and a substantial pipeline of over 4,400 additional beds.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)